TED Conjugate Segmentation for Intracellular Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development faces challenges in targeting and degrading specific proteins within cells, particularly due to limitations with small molecule drugs and antibody-drug conjugates, such as poor penetration and systemic toxicity, and the need for efficient protein degradation methods to treat diseases.
Innovation Solution
A conjugate with a specific structure, combining a target molecule moiety, a linker, and an E3 ligase ligand moiety, designed to bind to target proteins and facilitate their degradation through the ubiquitin-proteasome system, utilizing the cell's intrinsic protein destruction mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are used to target proteins, then drug concentration can be maintained in the body, but drug resistance develops and some target sites become non-drugable
Solution Approach 1:
The conjugate is divided into three functional segments: a target protein binding moiety (RT), a linker (L1), and an E3 ligase ligand moiety (RE3). This segmentation allows each component to perform its specific function independently - the RT binds to the target protein, the linker connects the components, and the RE3 recruits the E3 ligase, thereby overcoming the limitations of small molecule drugs in accessing certain target sites
Solution Approach 2:
The invention creates a composite molecular structure by combining different functional moieties (target protein binder, linker, and E3 ligase ligand) into a single conjugate molecule. This composite approach integrates the advantages of different molecular types, enabling the conjugate to bind target proteins with high specificity while also recruiting the ubiquitin-proteasome system for degradation, thus overcoming drug resistance and accessing previously non-drugable targets
2Reliability
If monoclonal antibodies are used to target proteins, then high affinity and selectivity are achieved, but cell membrane penetration is prevented and intracellular targets cannot be acted upon
Solution Approach 1:
The conjugate separates the targeting function (RT moiety that provides high affinity and selectivity) from the degradation function (RE3 moiety that recruits E3 ligase). This segmentation allows the RT to bind to the target protein with high specificity while the RE3 component enables intracellular degradation through the ubiquitin-proteasome system, effectively bypassing the cell membrane penetration limitation of intact antibodies
Solution Approach 2:
The linker L1 acts as an intermediary connecting the target protein binding moiety RT and the E3 ligase ligand moiety RE3. This intermediary structure allows the conjugate to function as a molecular bridge, enabling the transfer of the degradation signal from the extracellular binding event to the intracellular proteasome system
3Reliability
If antibody-drug conjugates are used to deliver toxins, then targeting is provided, but the treatment window is narrow due to side effects and toxin detachment
Solution Approach 1:
The invention converts the cell's natural protein degradation machinery (ubiquitin-proteasome system) into a therapeutic weapon. Instead of using exogenous toxins that cause systemic toxicity, the conjugate recruits the body's own E3 ligase and proteasome to selectively degrade the target protein, thereby eliminating the harmful side effects while maintaining targeting capability
Solution Approach 2:
The conjugate utilizes the cell's intrinsic ubiquitin-proteasome system to perform the degradation function. The E3 ligase ligand moiety RE3 recruits endogenous E3 ligase, which then ubiquitinates the target protein, marking it for degradation by the proteasome. This self-service approach eliminates the need for exogenous toxins and their associated toxicity issues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and reusable degradation of target proteins, improving drug selectivity and reducing systemic toxicity, thereby overcoming limitations of existing therapies.
Implementation Method 1
utilizing the cell's intrinsic protein destruction mechanism
Data Source
AI summary
The present invention relates to a targeted protease degradation (TED) platform, and specifically to a conjugate of target molecule-linker-E3 ligase ligand as shown in formula I, RT-L1-RE3 (formula I), wherein RT is a monovalent group of the target molecule, RE3 is a monovalent group of the E3 ligase ligand, L1 is the linker linking A and B, and L1 is as shown in formula II below: —W-L2-W2— (II).